Shares of Health Care sector company Guardant Health moved 0.2% today, and are now trading at a price of $61.84. The Mid-Cap stock's daily volume was 135,962 compared to its average volume of 2,575,079. The S&P 500 index returned a -1.0% performance.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company is based in Palo Alto and has 1,999 full time employees. Its market capitalization is $7,711,186,432.
22 analysts are following Guardant Health and have set target prices ranging from $47.0 to $80.0 per share. On average, they have given the company a rating of buy. At today's prices, GH is trading -10.21% away from its average analyst target price of $68.86 per share.
Over the last year, GH's share price has increased by 186.3%, which represents a difference of 171.9% when compared to the S&P 500. The stock's 52 week high is $68.0 per share whereas its 52 week low is $20.14. Guardant Health has averaged free cash flows of $-249555166.7 over the last 5 years, with a mean growth rate of -33.1%. It is unlikely that the stock can sustain its current performance trend for the long term when the underlying business is experiencing such poor cash flows.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | -239,858 | 35,085 | -274,943 | 20.41 |
| 2023 | -324,975 | 20,486 | -345,461 | 10.72 |
| 2022 | -309,463 | 77,461 | -386,924 | -36.22 |
| 2021 | -209,017 | 75,035 | -284,052 | -102.75 |
| 2020 | -103,927 | 36,173 | -140,100 | -112.75 |
| 2019 | -47,134 | 18,717 | -65,851 |
